The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | RASolute 302: additional subgroup analyses of daraxonrasib in pretreated PDAC
Zev Wainberg, MD, University of California, Los Angeles, CA, discusses additional subgroup analyses from the Phase III RASolute 302 study (NCT06625320), which compared daraxonrasib, an oral RAS(ON) multi-selective inhibitor, with standard-of-care chemotherapy in previously treated metastatic pancreatic adenocarcinoma (PDAC). The overall survival benefit seen in the primary analysis was observed across all RAS-mutated subgroups. The treatment effect was also consistent across the preselected chemotherapy regimens. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
